Study design
Nordisk Novo Pen
This study adopted a prospective, randomized, open, cross-controlled design, see Flow chart of cross test.Among them, the needle-free injection used was a Beijing fast-comfort (QS-M) needle-free syringe; the syringe injection used was a Novo Nordisk Novo Pen ⑤ and a disposable insulin syringe of size 31G 5mm×0.25mm from Becton, Dickinson (BD) and company. Intervention Phase 1 and Intervention Phase 2 patients in both groups were treated with insulin aspart 30 (pen core/refill) manufactured by Novo Nordisk, Denmark. The lower abdomen was selected as the route of administration for the two different ways of insulin injection. Peripheral blood glucose was monitored with an Essence blood glucose meter, transient scanning glucose monitoring was performed two (2) weeks after the first and second intervention phases. Health records and management was established for all the patients and strengthened. During the study period, the same health guidance was given to all the subjects, including insulin injections, diet control, regular follow-up, exercise and outpatient review. This was done to ensure effective data gathering.